

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONTRIBUTE	
09/965,703	00/26/2001		ATTORNET DOCKET NO.	CONFIRMATION NO.	
09/903,703	09/26/2001	Subba Reddy Palli	A01020B	8135	
7590 10/02/2003			EXAMINER		
RheoGene Ho 2650 Eisenhow			MURPHY, J	MURPHY, JOSEPH F	
Norristown, PA 19403			ART UNIT	PAPER NUMBER	
			1646	$\overline{\alpha}$	
			DATE MAILED: 10/02/2003	8	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		09/965,703	PALLI ET AL.				
		Examiner	Art Unit				
		Joseph F Murphy	1646				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status	•						
1)[1) $oxed{\boxtimes}$ Responsive to communication(s) filed on <u>26 September 2001</u> .						
2a)□	2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) 1-36 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-36</u> are subject to restriction and/or election requirement. Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
1	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a)	☐ The translation of the foreign language prov cknowledgment is made of a claim for domestic	isional application has been rece	ived.				
1) Notice 2) Notice 3) Inform	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) stent Application (PTO-152)				
U.S. Patent and Tra PTOL-326 (Re	a de	on Summary	Part of Paper No. 8				

Application/Control Number: 09/965,703

Art Unit: 1646

Page 2

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I-X. Claims 1-16, drawn to a gene expression modulation system comprising two expression vectors wherein the LBD of the first polypeptide is encoded by ONE of the following polynucleotides: SEQ ID NO: 1-10, classified in class 435, subclass 320.1.
- XI-XX.Claims 1-16, drawn to a gene expression modulation system comprising two expression vectors wherein the LBD of the first polypeptide is ONE of the following polypeptides: SEQ ID NO: 11-20, classified in class 435, subclass 320.1.
- XXI-XXX.Claims 1-16, drawn to a gene expression modulation system comprising two expression vectors wherein the LBD of the second polypeptide is encoded by ONE of the following polynucleotides: SEQ ID NO: 21-30, classified in class 435, subclass 320.1.
- XXXI-XL.Claims 1-16, drawn to a gene expression modulation system comprising two expression vectors wherein the LBD of the second polypeptide is ONE of the following polypeptides: SEQ ID NO: 31-40, classified in class 435, subclass 320.1.
- XLI-LXVIII.Claims 17-20, drawn to a gene expression cassette wherein the polynucleotide sequence comprises ONE of SEQ ID NO: 41, 43, 45, 47, 49, 51, 53, 1-10, 21-30, classified in class 435, subclass 320.1.

Application/Control Number: 09/965,703

Art Unit: 1646

LXIX-LXXXXIV.Claims 17-20, drawn to a gene expression cassette wherein the encoded polypeptide is ONE of the following: SEQ ID NO: 42, 44, 46, 48, 50, 52, 54, 11-20, 31-40, classified in class 435, subclass 320.1.

- LXXXXV-CXV.Claims 21-26 drawn to an isolated polynucleotide comprising ONE of the following: SEQ ID NO: 1-10, 21-30, classified in class 536, subclass 23.5.
- CXVI-CXXXVI.Claims 27-29, drawn to a polypeptide comprising ONE of the following: SEQ ID NO: 11-20, 31-40, classified in class 530, subclass 350.
- CXXXVII.Claims 30-32, drawn to a method of modulating the expression of a gene with a ligand, classified in class 435, subclass 7.8.
- CXXXVIII.Claims 35-36, as it is drawn to a transgenic non-human animal, classified in class 800, subclass 8.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-CXXXVI, CXXXVIII are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function, as evidenced by the different sequences set forth for each Group. Furthermore, given the differences in the structure of each Group, a search of art on one Group would not reveal art on the other Groups, thus imposing a burden to search on the Examiner.

Inventions I-CXXXVI, CXXXVIII and CXXXVIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown:

(1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of

Application/Control Number: 09/965,703

Art Unit: 1646

Page 4

using that product (MPEP § 806.05(h)). In the instant case the polynucleotide of Groups I-CXXXVI can be used as hybridization probes.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph F. Murphy whose telephone number is 703-305-7245. The examiner can normally be reached on M-F 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 703-308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Joseph F. Murphy, Ph. D.

Patent Examiner

Art Unit 1646

September 30, 2003

YUTTUNE CYLER, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600